Out to prove the next big I/O tar­get, Im­mu­ni­tas' chief deal­mak­er steps up to CEO role

To Aman­da Wag­n­er, the past two years or so she’s spent at Im­mu­ni­tas feels like a mi­cro­cosm of her en­tire ca­reer up to now.

Trained in neu­ro­science and equipped with an MBA, Wag­n­er’s 16-year bio­phar­ma ca­reer could be split in­to a first half in R&D and a sec­ond in cor­po­rate fi­nance and busi­ness de­vel­op­ment. She was con­sult­ing for the Long­wood Fund in 2019 when the VC firm pulled her aside to talk about a new im­muno-on­col­o­gy com­pa­ny it was in­cu­bat­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER